리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 193 Pages
라이선스 & 가격 (부가세 별도)
한글목차
에피네프린 자동 주사기 세계 시장은 2030년까지 36억 달러에 도달
2023년에 25억 달러로 추정되는 에피네프린 자동 주사기 세계 시장은 2023-2030년간 CAGR 4.8%로 성장하여 2030년에는 36억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 0.15gm 투여 에피네프린 자동 주사기는 CAGR 4.6%로 성장을 지속하고, 분석 기간이 끝날 때까지 25억 달러에 달할 것으로 예측됩니다. 0.30gm 투여 에피네프린 자동 주사기 부문의 성장은 향후 8년간의 CAGR이 5.6%로 예측됩니다.
미국 시장은 7억 5,610만 달러, 중국은 CAGR 4.5%로 성장할 것으로 예측
미국의 에피네프린 자동 주사기 시장은 2023년 7억 5,610만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023년부터 2030년까지의 분석 기간에서 CAGR 4.5%로 성장을 지속하여 2030년에는 6억 3,450만 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할만한 지리적 시장으로는 일본과 캐나다가 있으며, 각각 2023-2030년간 4.6%와 3.8%의 성장이 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 4.1%로 성장할 것으로 예측됩니다.
2024년을 위한 새로운 보고서의 특징
인플루언서의 참여 통계에 대한 전체 액세스
디지털 아카이브 및 "MarketGlass"리서치 플랫폼에 대한 무료 액세스. 당사의 고유한 MarketGlass 플랫폼은 전 세계 전문가의 창의성과 시장 지식을 통합적이고 협업적으로 제공합니다. 당사의 최첨단 도구는 참가자의 프라이버시와 정체성을 보호하면서 세계 수준 시장 전망을 제공합니다. 이 보고서에 게재된 숫자, 통계 및 시장에 대한 설명은 이 분야의 전문가와 인플루언서가 공유하는 완전하게 검토된 통찰력을 기반으로 합니다.
실시간 데이터 시뮬레이터 도구와 맞춤형 보고 기능을 갖춘 대화형 설문조사에 참여할 수 있습니다.
기업간의 스마트한 의견 교환을 위한 피어 콜라보레이티브 인터랙티브 플랫폼에의 풀 클라이언트 액세스
1년간의 무료 보고서 업데이트
주요 기업 세계 시장 점유율을 포함한 경쟁 적용 범위
여러 지역에 걸친 기업 시장 프레즌스 분석(호조/활발/틈새/마이너)
전문가/인플루언서 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연의 YouTube 동영상에 대한 액세스
2024년 세계경제에 기대
금융 계약과 그에 따른 금리 상승으로 인한 지정학적 영향과 경제 불안정성은 2024년 세계 경제를 파란으로 가득 찬 것으로 보입니다. 중동의 적대 행위와 점점 더 자주 발생하는 기후 재해와 같은 몇 가지 요인이 회복의 길에 압력을 가할 것입니다. 위험에 반해, 디스플레이션의 징후가 강해지고, 완고한 인플레이션에 대한 불안이 완화되고, 공급 체인이 정상화되고, 에너지 비용의 변동에도 불구하고 물가가 완만해지는 등, 몇 가지 플러스 재료도 구체화 계속 있습니다. 인도와 미국을 포함한 G21 국가의 선거는 자본 흐름과 투자 전략에 영향을 줄 수 있습니다. 인도가 세계적인 투자처로 주목받고 있는 한편, 미국을 거점으로 하는 하이테크 기업은 재능과 자본의 역동적인 에코시스템에 힘입어 계속 우위를 유지할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 감속하고 있다고는 해도 견고하고 규제 환경도 정비되어 있기 때문에 고성장 가능성을 요구하는 투자자에게 계속 매력적입니다. 유럽은 금융 계약 정책과 경기 후퇴 위험과의 싸움이 계속되고 있지만 영국은 전망이 가장 엄격하고 2024년경기 후퇴 위험이 가장 높습니다. 중국은 정부 지출과 개인 소비 개선에 뒷받침된 성장이 기대되는 것, 계속 와일드카드가 됩니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 모두 가져올 것으로 보입니다. 성장에 대한 촉매로서 변동성을 받아들이는 것과 동시에 민첩성과 전략적 선견성으로 투자 판단에 임하는 것이 생존을 위해 중요하다는 것은 변함이 없습니다.
조사 대상 기업 예(전 44건)
ALK-Abello A/S
Bausch Lomb UK Ltd-Emerade
Teva Pharmaceutical Industries Ltd.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
JHS
영문 목차
영문목차
Global Epinephrine Autoinjectors Market to Reach $3.6 Billion by 2030
The global market for Epinephrine Autoinjectors estimated at US$2.5 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.8% over the period 2023-2030. The 0.15 gm Dosage Epinephrine Autoinjectors, one of the segments analyzed in the report, is expected to record 4.6% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the 0.30 gm Dosage Epinephrine Autoinjectors segment is estimated at 5.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $756.1 Million, While China is Forecast to Grow at 4.5% CAGR
The Epinephrine Autoinjectors market in the U.S. is estimated at US$756.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$634.5 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 44 Featured) -
ALK-Abello A/S
Bausch + Lomb UK Ltd- Emerade
Teva Pharmaceutical Industries Ltd.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Epinephrine Autoinjectors - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Epinephrine Autoinjectors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Epinephrine Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for 0.15 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for 0.15 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for 0.30 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for 0.30 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for 0.5 gm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for 0.5 gm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 23: USA Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
CANADA
TABLE 26: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 29: Canada Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
JAPAN
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 32: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 35: Japan Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
CHINA
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 38: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 41: China Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
EUROPE
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 44: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Epinephrine Autoinjectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Epinephrine Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
FRANCE
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 53: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 56: France Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
GERMANY
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 59: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 62: Germany Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
ITALY
TABLE 65: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 68: Italy Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
UNITED KINGDOM
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 71: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 74: UK Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Rest of Europe Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Rest of Europe Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Rest of Europe 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Epinephrine Autoinjectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Asia-Pacific Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Asia-Pacific Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Asia-Pacific 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 89: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of World Historic Review for Epinephrine Autoinjectors by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2014, 2024 & 2030
TABLE 92: Rest of World Recent Past, Current & Future Analysis for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of World Historic Review for Epinephrine Autoinjectors by Dosage - 0.15 gm, 0.30 gm and 0.5 gm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of World 16-Year Perspective for Epinephrine Autoinjectors by Dosage - Percentage Breakdown of Value Sales for 0.15 gm, 0.30 gm and 0.5 gm for the Years 2014, 2024 & 2030